vs
Side-by-side financial comparison of Avidbank Holdings, Inc. (AVBH) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
Avidbank Holdings, Inc. is the larger business by last-quarter revenue ($28.0M vs $18.7M, roughly 1.5× CytomX Therapeutics, Inc.). Avidbank Holdings, Inc. runs the higher net margin — 32.3% vs -0.8%, a 33.1% gap on every dollar of revenue.
Avidbank Holdings, Inc. is a U.S.-based financial holding company operating through its subsidiary AvidBank. It offers commercial banking products and services primarily to small and medium-sized enterprises, business owners, and high-net-worth individuals across California, including commercial loans, deposit accounts, cash management, and customized financing solutions for sectors like manufacturing, technology, real estate and professional services.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
AVBH vs CTMX — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $28.0M | $18.7M |
| Net Profit | $9.0M | $-154.0K |
| Gross Margin | — | — |
| Operating Margin | — | -6.9% |
| Net Margin | 32.3% | -0.8% |
| Revenue YoY | — | -25.7% |
| Net Profit YoY | 65.9% | 97.6% |
| EPS (diluted) | $0.84 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $28.0M | — | ||
| Q4 25 | $26.8M | — | ||
| Q3 25 | $48.0K | — | ||
| Q2 25 | $21.8M | $18.7M | ||
| Q1 25 | — | $50.9M | ||
| Q4 24 | — | $38.1M | ||
| Q3 24 | — | $33.4M | ||
| Q2 24 | — | $25.1M |
| Q1 26 | $9.0M | — | ||
| Q4 25 | $6.9M | — | ||
| Q3 25 | $-37.7M | — | ||
| Q2 25 | $5.8M | $-154.0K | ||
| Q1 25 | — | $23.5M | ||
| Q4 24 | — | $18.9M | ||
| Q3 24 | — | $5.7M | ||
| Q2 24 | — | $-6.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -110491.7% | — | ||
| Q2 25 | 38.0% | -6.9% | ||
| Q1 25 | — | 44.4% | ||
| Q4 24 | — | 46.4% | ||
| Q3 24 | — | 12.3% | ||
| Q2 24 | — | -33.7% |
| Q1 26 | 32.3% | — | ||
| Q4 25 | 25.9% | — | ||
| Q3 25 | -78614.6% | — | ||
| Q2 25 | 26.6% | -0.8% | ||
| Q1 25 | — | 46.2% | ||
| Q4 24 | — | 49.6% | ||
| Q3 24 | — | 17.2% | ||
| Q2 24 | — | -26.0% |
| Q1 26 | $0.84 | — | ||
| Q4 25 | $0.65 | — | ||
| Q3 25 | $-4.12 | — | ||
| Q2 25 | $0.75 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $49.0M |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $287.2M | $119.9M |
| Total Assets | $2.5B | $175.1M |
| Debt / EquityLower = less leverage | 0.19× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $49.0M | ||
| Q1 25 | — | $47.6M | ||
| Q4 24 | — | $38.1M | ||
| Q3 24 | — | $40.6M | ||
| Q2 24 | — | $43.2M |
| Q1 26 | $55.0M | — | ||
| Q4 25 | $60.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $287.2M | — | ||
| Q4 25 | $278.4M | — | ||
| Q3 25 | $273.1M | — | ||
| Q2 25 | $204.4M | $119.9M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | — | $-456.0K | ||
| Q3 24 | — | $-23.5M | ||
| Q2 24 | — | $-31.2M |
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.4B | $175.1M | ||
| Q1 25 | — | $98.5M | ||
| Q4 24 | — | $120.5M | ||
| Q3 24 | — | $139.0M | ||
| Q2 24 | — | $159.2M |
| Q1 26 | 0.19× | — | ||
| Q4 25 | 0.22× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-15.8M |
| Free Cash FlowOCF − Capex | — | $-15.8M |
| FCF MarginFCF / Revenue | — | -84.6% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $12.4M | — | ||
| Q2 25 | $10.7M | $-15.8M | ||
| Q1 25 | — | $-21.0M | ||
| Q4 24 | — | $-19.9M | ||
| Q3 24 | — | $-20.7M | ||
| Q2 24 | — | $-19.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $12.4M | — | ||
| Q2 25 | $10.6M | $-15.8M | ||
| Q1 25 | — | $-21.2M | ||
| Q4 24 | — | $-20.0M | ||
| Q3 24 | — | $-20.7M | ||
| Q2 24 | — | $-19.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 25783.3% | — | ||
| Q2 25 | 48.6% | -84.6% | ||
| Q1 25 | — | -41.6% | ||
| Q4 24 | — | -52.5% | ||
| Q3 24 | — | -62.1% | ||
| Q2 24 | — | -78.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 72.9% | — | ||
| Q2 25 | 0.3% | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.84× | — | ||
| Q1 25 | — | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | — | -3.61× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVBH
| Net Interest Income | $26.5M | 95% |
| Noninterest Income | $1.5M | 5% |
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
